SCHEMBL4028259

SCHEMBL4028259

CC(C)(C)c1ccc(CNC(=O)c2cccc(Cl)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
CYP1A2 P05177 1/20 0.72
CYP2C19 P33261 1/20 0.72
RAB9A P51151 2/20 0.63
LMNA P02545 1/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63
NR1H4 Q96RI1 11/20 0.62
EPHX2 P34913 11/20 0.62
HDAC3 O15379 1/20 0.62
HDAC8 Q9BY41 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
NPC1 O15118 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
HPGD P15428 1/20 0.57
TSHR P16473 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12993420 0.84 RAB9A (0.88) MEN1KMT2ACYP1A2CYP2C19RAB9A
SCHEMBL27909695 0.83 NPC1 (0.71) MEN1KMT2ACYP1A2CYP2C19RAB9A
SCHEMBL11462330 0.82 NR1H4 (0.70) MEN1KMT2ACYP1A2CYP2C19RAB9A
SCHEMBL6557473 0.80 PPARA (0.70) MEN1KMT2ACYP1A2CYP2C19RAB9A
SCHEMBL3939260 0.80 MEN1 (0.56) MEN1KMT2ACYP1A2CYP2C19RAB9A
SCHEMBL4035947 0.80 RAB9A (0.65) MEN1KMT2ARAB9ALMNANR1H4
SCHEMBL17339269 0.80 CA1 (0.64) MEN1KMT2ACYP1A2CYP2C19RAB9A
SCHEMBL5333738 0.79 TSHR (0.66) MEN1KMT2ACYP1A2CYP2C19RAB9A
SCHEMBL14860031 0.79 MTOR (0.72) MEN1KMT2ACYP1A2CYP2C19RAB9A
SCHEMBL7302861 0.79 NPC1 (0.70) MEN1KMT2ARAB9AHDAC3HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090171091-A1 COMPOUNDS SUITABLE AS MODULATORS OF HDL CADILA HEALTHCARE LIMITED (IN) 2009-07-02 US claimed
EP-2049493-A2 COMPOUNDS SUITABLE AS MODULATORS OF HDL Cadila Healthcare Limited (IN) 2009-04-22 EP claimed
WO-2008059513-A2 COMPOUNDS SUITABLE AS MODULATORS OF HDL CADILA HEALTHCARE LIMITED (IN) 2008-05-22 WO claimed
US-20090171091-A1 COMPOUNDS SUITABLE AS MODULATORS OF HDL CADILA HEALTHCARE LIMITED (IN) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090171091-A1 COMPOUNDS SUITABLE AS MODULATORS OF HDL CETP, APOB, HDLBP MEN1 1778/4885KMT2A 4396/4885CYP1A2 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.